Enzalutamide vs Bicalutamide in CRPC: The STRIVE trial
Primary endpoints:
l
id
Patient population:
Progression‐free
survival:
Enza utam e
160 mg/day
(capsules)
n 198
R
A
N
•
M0 or M1 CRPC
•
Asymptomatic/
mildly symptomatic
‐
Radiographic
progression
or
=
D
O
M
I
•
Chemotherapy‐naïve
•
No prior bicalutamide or no
progression on bicalutamide
‐
PSA progression
or
Death
Bicalutamide
Z
E
D
‐
50 mg/day
N=198
1:1
Penson D, et al. J Clin Oncol 2016
